MARLBOROUGH, Massachusetts,
July 5, 2018 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) announced today that its
Panther Fusion® MRSA assay has received CE-mark in
Europe. This assay, the latest in
a growing menu of Panther Fusion® and Aptima® assays, brings full
automation, efficiency and excellent assay performance to MRSA
screening. The Panther Fusion system retains all the key benefits
of the Panther platform, including full sample-to-result
automation, and is suitable to any size laboratory.
"The launch of the Panther Fusion® MRSA assay
demonstrates our commitment to expanding the portfolio of assays
available for Panther Fusion, enabling our European customers to
deliver a better service to their clients and ultimately to
patients," said João Malagueira, Vice President Diagnostics
EMEA. "With rising antibiotic resistance in Europe and the threat posed by
healthcare-associated infections to public health, our new assay
will help customers provide a rapid service to hospitals, so cases
of resistance, such as MRSA, are identified and managed quickly and
effectively."
The Panther Fusion MRSA assay accurately detects and
differentiates Staphylococcus aureus (SA) and
methicillin-resistant Staphylococcus aureus (MRSA) DNA from
ESwab™ nasal samples. It has broad strain inclusivity including the
Bengal Bay clone, and is able to correctly identify empty cassette
variants.
The Panther Fusion® MRSA assay enables laboratory
customers to leverage the benefits of the fully automated Panther
Fusion system, which provides random and continuous access to
improve laboratory efficiency. Laboratories can combine Women's
Health, Virology, Respiratory, Hospital-Acquired Infections, and
Open Access® tests on the Panther Fusion system, running up to 32
different assays at the same time. In addition, MRSA samples can be
loaded directly into the Panther Fusion, saving customers vital
time and labor costs and delivering first results in 2.4 hours,
considerably faster than commonly used culture and lab developed
tests. In addition, Panther Fusion offers labs the potential
to process up to 500 Panther Fusion and Aptima assays in an 8-hour
period.
Panther Fusion is available as a full system, or the Panther
Fusion module can be attached to existing Panther systems in the
field to extend testing capabilities. The Panther Fusion module
adds the capacity to run PCR (polymerase chain reaction) assays in
addition to tests based on TMA (transcription-mediated
amplification), the proprietary Hologic chemistry that powers the
Company's Aptima® brand. Key benefits include the ability to
run multiple tests from a single sample, random and continuous
access, sample processing with rapid turnaround time, continuous
loading, and STAT capabilities. Its ready to use, unit-dose
lyophilized reagents, which have 60-day on-board stability, help
reduce waste and the need for manual reagent preparation.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information
on Hologic, visit www.hologic.com.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic's diagnostic products. There can be no assurance
these products will achieve the benefits described herein or that
such benefits will be replicated in any particular manner with
respect to an individual patient, as the actual effect of the use
of the products can only be determined on a case-by-case basis. In
addition, there can be no assurance that these products will be
commercially successful or achieve any expected level of sales.
Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any
change in events, conditions or circumstances on which any such
data or statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
Hologic, Panther, Panther Fusion, Aptima and The Science of Sure
are trademarks and/or registered trademarks of Hologic, Inc. in
the United States and/or other
countries.
Media Contact:
Jane
Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael
Watts
+1 858.410.8588
michael.watts@hologic.com